Table 4 |
|||||
|
MULTIPLE METABOLIC TOXICITIES IN MS AND T2DM: THE A-FLIGHT ACRONYM |
|||||
|
Initiator |
Metabolic Defect |
Metabolic mediator |
Functional mediator |
Consequence |
|
|
|
|||||
|
A |
AMYLIN (Co-secreted – Co-packaged within the insulin secretory granule) by the islet Beta cell. Insulin's "Fraternal Twin" Elevated in MS, PD, and Early T2DM) |
Hyperamylinemia |
Activation of ANG II |
PKC Signal Transduction Islet Amyloid IAPP Islet aggregation and deposition. Beta cell apoptosis – Beta cell defect. |
ROS IAPP Amyloid in islets contributing to Beta Cell defect. Possible deposition in the intima, mesangium, neuronal unit, and myocardial. REMODELING |
|
ANG II Via RAAS activation In MS, PD, and T2DM |
Ang II Excess |
Ang II Excess Most potent stimulus for: Activation of Vascular membrane bound NAD(P)H Oxidase Enzyme |
PKC Signal Transduction. Superoxide production. Uncoupling of the eNOS reaction. TGF beta-1 activation |
ROS NAD(P)H oxidase Derived Superoxide Myocardial, Renal, Intimal, Retinal, and Neuronal remodeling |
|
|
AGE Advanced Glycation Endproducts AFE Advanced fructosylation endproducts |
AGE / AFE See Glucotoxicity (G) RAGE activation Receptor for AGE |
Protein Cross – linking / Dysfunction RAGE Receptor for AGE |
Matrix Defects Signal Transduction Matrix Defects Signal Transduction |
ROS Myocardial, Renal, Intimal, Retinal, Neuronal – Endoneurial Fibrosis |
|
|
Advanced Lipoxidation Endproducts (ALE) |
ALE |
Protein Cross – linking |
Matrix Defects Signal Transduction |
ROS Matrix Remodeling |
|
|
AntioxidantEnzymes: Antioxidant reserve compromised |
Reduced – Dysfunctional eNOS, SOD, GPx, GSH, Catalase, and Vit. C. |
Decreased NO |
Decreased NO REDOX STRESS |
ROS REDOX STRESS |
|
|
AntioxidantEnzymes: Absence of antioxidant network |
IMPAIRED eNOS L-arginine BH4 |
Decreased NO |
Decreased NO |
ROS Decreased NO |
|
|
AGING: Accumulation of multiple metabolic toxicities → ROS |
Increased Ox-LDL-C, TNFalpha, Capase 3, Glomerulosclerosis. |
Decreased NO: |
Decreased NO |
ROS Inflammation, Apoptosis |
|
|
Atherosclerotic Nephropathy |
ROS beget ROS Atheroscleropathy |
Decreased NO Self perpetuating Decreased NO |
Decreased NO Athero – emboli Activated Platelets See Thrombotic Tox. |
ROS beget ROS Decreased NO |
|
|
F |
Free fatty acid toxicity |
Elevated FFA |
LC acyl -CoA's |
Mitochondrial Defects |
ROS Cytotoxicity |
|
L |
Lipotoxicity Lipid Triad FFA ALE Long chain acyl-COA's |
Increased VLDL – VLDL Triglycerides and Small dense atherogenic LDL-Cholesterol with Decreased HDL-Cholesterol LIPID TRIAD |
LC acyl -CoA's Fat Accumulation |
Non Adipose Accumulation of Fat (LC acyl -CoA's) in Adipose and Non Adipose Tissue |
ROS Accumulation of fat in non adipose tissues resulting in Ceramide induced: Cytotoxicity |
|
I |
Insulin toxicity ENDOGENOUS Insulin Resistance |
Hyperinsulinemia Hyperamylinemia in : MS, PD, EARLY T2DM Glut 4 is NO dependent Redox sensitive pathway |
Ang II Increase # AT-1 receptors Cross-talk with AT-1 Increase FFA Increase PAI-1 Increase Sympathetic tone and activity Increased Na+ and H2O reabsorption Increase Volume and Blood Pressure Hypertension Hype |
NAD(P)H REDOX STRESS SIGNAL PATHWAYS PI3 Kinase / Akt (Protein kinase B)→ MAP Kinase Shunt |
ROS ROS ROS Extracellular Matrix Remodeling Islet, intimal, renal, myocardial, and neuronal. |
|
Inflammation toxicity. "Inflammatory Cycle" (figure 5) |
Activation of the innate immune system: IL-6, IL-8, TNF alpha Macrophage (MPO) → Hypochlorous Acid Superoxide O2• |
Acute Phase Reactants: C-Reactive Protein Serum Amyloid A Fibrinogen |
NF kappa B Cellular Adhesion Molecules: ICAM, VCAM, and MCP-1 |
ROS Inflammation begets Inflammation " INFLAMMATORY CYCLE " (figure 5) ROS beget ROS |
|
|
Insulin deficiency |
OVERT T2DM |
GLUCOTOXICITY POLYOL SORBITOL PATHWAY |
REDUCTIVE STRESS NADH > NAD+ PSEUDOHYPOXIA |
ROS |
|
|
G |
Glucotoxicity |
Glycation / AGE |
See above |
See above |
See above |
|
Protein inactivation |
Receptor-ligand defects |
Dysfunctional Signal Transduction |
|||
|
NO quenching |
Vasoconstriction |
Ischemia/Hypoxia ROS |
|||
|
Macrophage Activation |
Increased Cytokines, TGF-Beta |
Cytotoxicity ROS |
|||
|
Free Radical Formation |
REDOX STRESS |
Cytotoxicity ROS |
|||
|
Auto-oxidation |
Free Radical Formation |
REDOX STRESS |
Cytotoxicity ROS |
||
|
ORIGIN OF REDUCTIVE STRESS ! REDUCTIVE STRESS ! |
Polyol Sorbitol Pathway (eNO inhibits Aldose Reductase) |
Increased NADH Lactate Reductive Stress |
REDOX STRESS Decreased NO Pseudohypoxia |
Cytotoxicity ROS Ischemia/ Hypoxia |
|
|
Decreased Taurine |
REDOX STRESS |
ROS Cytotoxicity |
|||
|
Increased DAG |
Increased PKC |
Signal Transduction |
Ischemia ROS |
||
|
Glucotoxicity |
Glucotoxicity |
Polyol – Sorbitol Pathway |
PAS + material Interstitium, Basement Membrane |
Remodeling – Cardiomyopathy CHF Diastolic Dysfunction |
|
|
H |
Hypertension Toxicity Homocysteine Toxicity |
RAAS activation HHcy NO quenching and NEW: PPAR interaction. |
Ang II Decreased GPx, DDAH with resultant ^ ADMA |
NAD(P)H REDOX STRESS ^ ROS, O2', ONOO', nitrotyrosine |
ROS Decreased NO, Endothelial Cell toxicity, dysfunction, and apoptosis |
|
T |
Triglyceride Toxicity Thrombotic Toxicity Taurine (antioxidant) depletion |
Triglyceride – FFA exchange |
See FFA – Lipotoxicity above eNOS uncoupling |
REDOX STRESS Activated Platelets PAI-1 elevation Fibrinogen elevated. Decreased NO |
ROS Athero-emboli ROS |
|
|
|||||
|
Hayden and Tyagi Nutrition Journal 2004 3:4 doi:10.1186/1475-2891-3-4 |
|||||